Nanotein Technologies, Inc., a San Francisco Bay Area-based biotechnology startup, and Polaris Group, a developer of novel cancer therapies, announced today that they have established a strategic partnership to advance Nanotein’s superior protein-based cell therapy manufacturing solutions.
As part of the agreement, Polaris will produce GMP-grade materials for Nanotein for research use only. Polaris will receive equity and royalties for its manufacturing services. Nanotein’s novel cell activation and expansion reagents enable the production of best-in-class cell therapies at a lower cost and faster pace than the few existing competitive reagents.
Nanotein Technologies, Inc.
Nanotein’s cell therapies, such as chimeric antigen receptor T-cell (CAR T) therapy, represent a highly promising new cancer treatment modality poised for significant growth in the near term.